AU2001295700A1 - Monoclonal antibodies directed against hepatitis b viruses - Google Patents

Monoclonal antibodies directed against hepatitis b viruses

Info

Publication number
AU2001295700A1
AU2001295700A1 AU2001295700A AU9570001A AU2001295700A1 AU 2001295700 A1 AU2001295700 A1 AU 2001295700A1 AU 2001295700 A AU2001295700 A AU 2001295700A AU 9570001 A AU9570001 A AU 9570001A AU 2001295700 A1 AU2001295700 A1 AU 2001295700A1
Authority
AU
Australia
Prior art keywords
viruses
monoclonal antibodies
directed against
antibodies directed
against hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295700A
Inventor
Nicole Battail-Poirot
Laurence Becquart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Publication of AU2001295700A1 publication Critical patent/AU2001295700A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a monoclonal antibody capable of binding to a wild-type HBsAg antigen and to at least one, preferably at least two and advantageously more than two, mutant forms of the HBsAg antigen, said monoclonal antibody binding to a peptide sequence consisting of at least 6 contiguous amino acids in the 199-208 region of the HBsAg antigen, and advantageously binding to the peptide sequence constituted by the 199-208 region of the HBsAg antigen.
AU2001295700A 2000-10-20 2001-10-12 Monoclonal antibodies directed against hepatitis b viruses Abandoned AU2001295700A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0013454A FR2815634B1 (en) 2000-10-20 2000-10-20 MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUSES
FR0013454 2000-10-20
PCT/FR2001/003169 WO2002034789A1 (en) 2000-10-20 2001-10-12 Monoclonal antibodies directed against hepatitis b viruses

Publications (1)

Publication Number Publication Date
AU2001295700A1 true AU2001295700A1 (en) 2002-05-06

Family

ID=8855552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295700A Abandoned AU2001295700A1 (en) 2000-10-20 2001-10-12 Monoclonal antibodies directed against hepatitis b viruses

Country Status (9)

Country Link
US (1) US7785586B2 (en)
EP (1) EP1326895B8 (en)
JP (1) JP4293788B2 (en)
AT (1) ATE312846T1 (en)
AU (1) AU2001295700A1 (en)
DE (1) DE60115938T2 (en)
ES (1) ES2252301T3 (en)
FR (1) FR2815634B1 (en)
WO (1) WO2002034789A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550558B2 (en) * 2001-06-01 2009-06-23 Fundacao De Ampara A Pesquiso Do Estado De Sao Paolo (Fapesp) Antimicrobial peptides and methods for identifying and using such peptides
PT1766098E (en) * 2004-06-07 2014-08-22 Novartis Vaccines & Diagnostic Rabbit monoclonal antibodies to hepatitis b surface antigens and methods of using the same
US20110097270A1 (en) * 2005-01-14 2011-04-28 Schofield Darren J Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus
JP4948783B2 (en) * 2005-05-18 2012-06-06 シスメックス株式会社 Anti-HBs monoclonal antibody
MY178496A (en) 2012-07-10 2020-10-14 Green Cross Corp Antibody composition for prevention or treatment of mutant hepatitis b virus infection
KR101646830B1 (en) * 2013-05-31 2016-08-08 (주)셀트리온 A binding molecule able to neutralize Hepatitis B virus
US9714284B2 (en) * 2013-07-16 2017-07-25 National Health Research Institutes Antibodies and method for determining deletions in HBV pre-S2 region
CN104845938B (en) * 2015-04-17 2018-07-03 北京科兴中维生物技术有限公司 Hepatitis b virus s antigen monoclonal antibody and its application
CN111234013B (en) * 2018-11-29 2022-01-11 清华大学 Neutralizing antibody B430 of hepatitis B virus and application thereof
WO2023143445A1 (en) * 2022-01-25 2023-08-03 厦门大学 Epitope peptide and antibody for treating hbv infection and related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204095A (en) * 1980-04-09 1993-04-20 National Research Development Corporation Monoclonal antibodies against hepatitis B virus
GB9007024D0 (en) * 1990-03-29 1990-05-30 Imperial College Novel vaccine
US6030616A (en) * 1993-03-24 2000-02-29 Imperial College Of Science, Technology & Medicine Hepatitis B escape mutant specific binding molecules
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization

Also Published As

Publication number Publication date
JP4293788B2 (en) 2009-07-08
JP2004516824A (en) 2004-06-10
FR2815634A1 (en) 2002-04-26
EP1326895A1 (en) 2003-07-16
EP1326895B8 (en) 2006-06-21
WO2002034789A1 (en) 2002-05-02
ATE312846T1 (en) 2005-12-15
ES2252301T3 (en) 2006-05-16
US20040219154A1 (en) 2004-11-04
US7785586B2 (en) 2010-08-31
DE60115938D1 (en) 2006-01-19
EP1326895B1 (en) 2005-12-14
DE60115938T2 (en) 2006-07-27
FR2815634B1 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
PT1135498E (en) Antibody variants with higher binding affinity compared to parent antibodies
ATE125821T1 (en) VACCINE AGAINST HEPATITIS B.
EP0608261A4 (en) Immunoreactive hepatitis c virus polypeptide compositions.
JP2002533123A5 (en)
AU5249501A (en) Synthetic peptides that bind to the hepatitis b virus core and e antigens
HK1038069A1 (en) Immunoassay for c.reactive protein
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
WO1999003987A3 (en) Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
EP1326895B8 (en) Monoclonal antibodies directed against hepatitis b viruses
MX9603182A (en) Hepatitis b vaccine.
DE60234085D1 (en) RECOMBINANT SUPER-COMPOUND INTERFERON FOR USE AS HEPATITIS B SURFACE NATURES AND E-ANTIGEN INHIBITOR
AU6276301A (en) A variable region of the monoclonal antibody against the hbv s-surface antigen and a gene encoding the same
CA2351315A1 (en) Humanized antibody specific for surface antigen pre-s1 of hbv and preparation method thereof
CA2080548A1 (en) Monoclonal antibodies to hepatitis c virus
WO1995016040A3 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
DE60324003D1 (en) Hcv-test
WO1994021812A3 (en) Hepatitis b escape mutant specific binding molecules
WO2002023202A8 (en) Method to identify antibody targets based on mass spectrometry (maldi-tof)
WO2001093804A3 (en) Hepatitis c virus conjugates
WO2000042194A3 (en) Mutant hepatitis b surface antigen and testing
GR3036125T3 (en) Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines.
WO1999019358A3 (en) Antibody against baculoviruses
ATE352621T1 (en) ANTIBODY MUTANT